60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
WATERTOWN, Mass. - Disc Medicine, Inc. (NASDAQ:IRON) announced it will present initial data from its RALLY-MF Phase 2 trial of DISC-0974 for anemia in myelofibrosis patients at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando, Florida on December 6-9, 2025. The clinical-stage biotech, currently valued at approximately $3 billion, has seen its stock surge 83% over the past year according to InvestingPro data.
The clinical-stage biopharmaceutical company will showcase two poster presentations at the conference. The first poster will feature preliminary results from the RALLY-MF trial, which is evaluating DISC-0974 both as a monotherapy and in combination with JAK inhibitors including ruxolitinib and momelotinib. The second poster will outline the design of the company's ongoing Phase 2 trial of DISC-3405 in polycythemia vera.
"Following the strong Phase 1b results we presented at ASH last year, we are eager to share an update on this program, including results from more patients from across the range of MF anemia patients," said John Quisel, President and Chief Executive Officer of Disc Medicine, in a press release statement.
The company plans to host a conference call on December 7 to discuss the presented data and outline next steps in development.
Disc Medicine also noted that initial readouts for its Phase 2 trial of DISC-3405 in polycythemia vera and Phase 1b trial of the same drug in sickle cell disease are expected in 2026.
The ASH abstracts published today contain previously presented data, with new data and analyses reserved for presentation at the conference. The DISC-0974 poster presentation is scheduled for December 6 at 5:30 pm EST, with Dr. Naseema Gangat as the presenting author.
Disc Medicine focuses on developing treatments for serious hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. Despite not being profitable, the company holds more cash than debt on its balance sheet and maintains a current ratio of 32.1, indicating strong liquidity to fund its clinical programs. Analysts remain bullish with a strong buy consensus and a high price target of $153, according to InvestingPro, which offers a comprehensive research report on this stock among 1,400+ US equities covered by their deep-dive analysis.
In other recent news, Disc Medicine has priced an upsized public offering valued at approximately $250 million. The company is selling shares of common stock and pre-funded warrants, while AI DMI LLC is also offering shares. Additionally, Disc Medicine has launched another stock offering worth $220 million to support the commercialization of bitopertin and fund further research and development. The company has submitted a New Drug Application for bitopertin in erythropoietic protoporphyria, receiving a priority review that could lead to approval by late 2025 or early 2026.
Analyst firm Raymond James has reiterated its Strong Buy rating on Disc Medicine, citing the potential of DISC-0974 as a future growth driver. Wells Fargo has also maintained its Overweight rating with a price target of $91.00, reflecting a positive outlook on the company. These developments highlight Disc Medicine's ongoing efforts in advancing its drug pipeline and securing financial resources for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.